NEW YORK, July 30, 2012 /PRNewswire/ -- Icon plc (NASDAQ: ICLR: $24) has been picked by S&P Capital IQ as its Focus Stock of the Week. ICLR's American depositary shares (ADSs) carry S&P Capital IQ's highest investment recommendation of 5-STARS, or Strong Buy. ICLR is a leading global contract research organization (CRO) providing outsourced clinical research and development services to the pharmaceutical, biotechnology, and medical devices industries.
"Large pharmaceutical companies are continually seeking to drive efficiencies in their drug development processes to reduce costs associated with the development of new drug candidates and accelerate time to market," said Jeffrey Loo, equity analyst at S&P Capital IQ. "This has resulted in pharmaceutical firms increasingly outsourcing various research and development functions to CROs, and we believe the main beneficiaries are the larger global CROs such as ICLR."
To view a video of Mr. Loo discussing ICLR click on the following link.
Weblink to video
About S&P Capital IQ S&P Capital IQ, a business line of the McGraw-Hill Companies (NYSE: MHP), is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. We provide a broad suite of capabilities designed to help track performance, generate alpha, identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Valuations, and Compustat; and research offerings, including Leveraged Commentary & Data, Global Market Intelligence, and company and fund research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit www.spcapitaliq.com.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV